Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2018 Filed Feb 23, 2018 21:14 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionCommon Stock | 1,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004013 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Pierce David ASVP,Pres Urology,Pelvic Health
|
Exercise / conversionDeferred Stock Units · Derivative | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004012 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,821 Underlying: Common Stock · 2,607 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Pierce David ASVP,Pres Urology,Pelvic Health
|
Tax withholdingCommon Stock | 1,159 | $26.48 | $30,690.32 |
DisclosureSEC source: 0001225208-18-004012 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,649 Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Pierce David ASVP,Pres Urology,Pelvic Health
|
Exercise / conversionCommon Stock | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004012 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionDeferred Stock Units · Derivative | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004010 · doc4.xml · derivative · entry 3 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,387 Underlying: Common Stock · 2,462 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Tax withholdingCommon Stock | 944 | $26.48 | $24,997.12 |
DisclosureSEC source: 0001225208-18-004010 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,738 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004010 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionDeferred Stock Units · Derivative | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004009 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,649 Underlying: Common Stock · 1,883 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Tax withholdingCommon Stock | 652 | $26.48 | $17,264.96 |
DisclosureSEC source: 0001225208-18-004009 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,452 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004009 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionDeferred Stock Units · Derivative | 2,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004007 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,953 Underlying: Common Stock · 2,317 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 710 | $26.48 | $18,800.80 |
DisclosureSEC source: 0001225208-18-004007 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,355 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004007 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionDeferred Stock Units · Derivative | 23,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004006 · doc4.xml · derivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,525 Underlying: Common Stock · 23,175 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 10,302 | $26.48 | $272,796.96 |
DisclosureSEC source: 0001225208-18-004006 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,072,066 Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 23,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004006 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,082,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionDeferred Stock Units · Derivative | 2,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004005 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,691 Underlying: Common Stock · 2,897 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mackey Edward FEVP, Operations
|
Tax withholdingCommon Stock | 854 | $26.48 | $22,613.92 |
DisclosureSEC source: 0001225208-18-004005 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,282 Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionCommon Stock | 2,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004005 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionDeferred Stock Units · Derivative | 4,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004004 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,168 Underlying: Common Stock · 4,055 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Tax withholdingCommon Stock | 1,850 | $26.48 | $48,988.00 |
DisclosureSEC source: 0001225208-18-004004 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,642 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionCommon Stock | 4,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004004 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 2,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004002 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,953 Underlying: Common Stock · 2,317 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 879 | $26.48 | $23,275.92 |
DisclosureSEC source: 0001225208-18-004002 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,755 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 2,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004002 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 1,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004001 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,042 Underlying: Common Stock · 1,014 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Tax withholdingCommon Stock | 531 | $26.48 | $14,060.88 |
DisclosureSEC source: 0001225208-18-004001 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,166 Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionCommon Stock | 1,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004001 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:10 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionDeferred Stock Units · Derivative | 3,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003998 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,298 Underlying: Common Stock · 3,766 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:10 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 1,718 | $26.48 | $45,492.64 |
DisclosureSEC source: 0001225208-18-003998 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,095 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:10 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 3,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003998 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionDeferred Stock Units · Derivative | 5,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003999 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,382 Underlying: Common Stock · 5,793 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 2,575 | $26.48 | $68,186.00 |
DisclosureSEC source: 0001225208-18-003999 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,027 Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:11 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 5,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003999 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 21:13 UTC |
Pierce David ASVP,Pres Urology,Pelvic Health
|
SaleCommon Stock | 16,286 | $27.00 | $439,722.00 |
DisclosureSEC source: 0001225208-18-004012 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $27.00 and $27.005. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:59 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
GrantStock Option (Right to Buy) · Derivative | 20,856 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003404 · doc4.xml · derivative · entry 2 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,856 Underlying: Common Stock · 20,856 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:59 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
GrantDeferred Stock Units · Derivative | 6,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003404 · doc4.xml · derivative · entry 1 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,921 Underlying: Common Stock · 6,921 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
GrantStock Option (Right to Buy) · Derivative | 27,808 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003403 · doc4.xml · derivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,808 Underlying: Common Stock · 27,808 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
GrantDeferred Stock Units · Derivative | 9,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003403 · doc4.xml · derivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,228 Underlying: Common Stock · 9,228 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
GrantStock Option (Right to Buy) · Derivative | 18,075 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003402 · doc4.xml · derivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,075 Underlying: Common Stock · 18,075 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
GrantDeferred Stock Units · Derivative | 5,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003402 · doc4.xml · derivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Stock · 5,998 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Ralls-Morrison DesireeSVP, GC and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 16,685 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003401 · doc4.xml · derivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,685 Underlying: Common Stock · 16,685 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Ralls-Morrison DesireeSVP, GC and Secretary
|
GrantDeferred Stock Units · Derivative | 5,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003401 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,537 Underlying: Common Stock · 5,537 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Pierce David ASVP,Pres Urology,Pelvic Health
|
GrantStock Option (Right to Buy) · Derivative | 41,713 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003400 · doc4.xml · derivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,713 Underlying: Common Stock · 41,713 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Pierce David ASVP,Pres Urology,Pelvic Health
|
GrantDeferred Stock Units · Derivative | 13,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003400 · doc4.xml · derivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,842 Underlying: Common Stock · 13,842 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantStock Option (Right to Buy) · Derivative | 25,027 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003399 · doc4.xml · derivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,027 Underlying: Common Stock · 25,027 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantDeferred Stock Units · Derivative | 8,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003399 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,305 Underlying: Common Stock · 8,305 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:56 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GrantStock Option (Right to Buy) · Derivative | 30,589 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003390 · doc4.xml · derivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,589 Underlying: Common Stock · 30,589 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:56 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GrantDeferred Stock Units · Derivative | 10,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003390 · doc4.xml · derivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,151 Underlying: Common Stock · 10,151 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:56 UTC |
Meredith Ian TEVP/ Global Chief Medical Offi
|
GrantStock Option (Right to Buy) · Derivative | 16,685 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003389 · doc4.xml · derivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP/ Global Chief Medical Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,685 Underlying: Common Stock · 16,685 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.